Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03763149
Title A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Innovent Biologics (Suzhou) Co. Ltd.
Indications

lymphoma

Advanced Solid Tumor

Therapies

IBI188

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.